Zealand Pharma has listed on the Nasdaq Global Select Market in addition to its listing in Copenhagen, raising USD 89 in the process. But the move does not mean the biotech company has lost faith in the Danish investor base, says CEO Britt Meelby Jensen.
Genmab’s Darzalex royalties now cover the company’s operating costs and in addition to that, the cancer drug continues its expansion to new markets. And according to CEO, Jan van de Winkel, Genmab could potentially raise its guidance this year.
Denmark’s ALK is ready to go “full steam” in the launch of a promising tablet against house dust mite allergy on the US market as early as this year. The only obstacle is a formal handover of the marketing permit from former partner Merck, which could push the launch into 2018.
Bioporto’s sales of antibodies and the kidney test NGAL for research use have grown rapidly in 2017. Despite this, the company is forced to downgrade its financial expectations, now expecting a larger deficit for the year. But there is a perfectly good reason for that, explains the CEO.
The US competitor to Lundbeck’s epilepsy drug Sabril is long in coming and this is partly the reason behind the new guidance hike for the Danish company. In the first half year of 2017, Sabril continued to gain market shares in the US.
Once again, Novo Holdings has led a sizeable investment round in North America. The company gets a position on the board of the new portfolio company, which develops a nasal spray against atrial fibrillation.
Molecular researchers from the University of Copenhagen have teamed up with the US-based company Insilico Medicine specialized in artificial intelligence. The hope is to develop new drugs against age-related diseases such as Alzheimer’s, Parkinson’s, and cardiovascular diseases.
Lundbeck is looking for 25,000 people for a major research project. The aim is to get a better knowledge about what factors affect the development of Major Depressive Disorder (MDD) and Bipolar Depression.
Genmab’s CEO is ecstatic over the biotech's “shining star”, bone marrow cancer drug Darzalex. He doubts he will see anything like it in his time in the company, but is working intently on finding a new cash cow.
Norway-based financial services group DNB believes the Oslo Cancer Cluster has developed into one of Europe’s top biotech hubs. Norway’s life science industry is generally speaking more mature than a few years ago, says the group’s senior advisor for healthcare.
The global hearing device industry is currently benefitting from an ageing population. But what is going to drive growth when the demographic trend is reversed? MedWatch spoke to the Danish industry majors about the issue.